Aventis Faces Threat Of Generic Competition For Lovenox
A U.S. biotechnology company headed for an initial public offering plans to produce a generic version of Aventis' anti-blood clotting drug Lovenox....To view the full article, register now.
Already a subscriber? Click here to view full article